Biblio

Export 7 results:

Szűrők: Szerző is Holopainen, Tanja [Minden szűrő visszaállítása]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

V

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974

Maija Bry et al., Circulation 2010 (2.23 MB)

Maija Bry et al., Circulation 2010, supplement (17.77 MB)

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292

Yulong He et al., Cancer Research 2005 (1.82 MB)

T

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522

Caroline Heckman et al., Cancer Research 2008 (504.8 KB)

I

Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809

Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)

E

Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, et al.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043

Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)

Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)

C

CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract

Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB)

Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB)

Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB)

B

The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52.

Anisimov 2013 Science Signaling (1.92 MB)

Anisimov 2013 Science Signaling Supplement (2.09 MB)